CD19 and acute lymphoblastic leukemia: Bai et al.31 reported data for 12 patients with acute lymphoblastic leukemia (ALL) treated with a CD19 CAR-T product analogous to Kymriah—five CRs, two NRs and five patients who relapsed (RL).